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Summary 
 
 
The long-term treatment of peritumoral edema remains a major challenge in clinical 
neurooncology. Steroids have been and will remain the backbone of any anti-edematous 
therapy because of their striking activity, convenient oral administration and also because of 
their cost effectiveness. Their side effects, however, can compromise quality of life, 
particularly upon continuous administration. Therapeutic alternatives which may replace or – 
at least – help to reduce the steroid dose are limited. However, with the development of new 
agents such as corticorelin acetate, there is hope that steroid-induced side effects can be 
delayed and reduced. The administration of anti-angiogenic agents with steroid-sparing 
effects, e.g. bevacizumab, is limited due to their costs. Increased knowledge on boswellic 
acids and COX-2 inhibitors which are available for clinical application may help to exploit 
their anti-edema activity more efficiently in the future. 
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Background 
 
Peritumoral edema is a typical finding of malignant neoplasms of the central nervous system 
(CNS) such as high-grade gliomas and metastases. It can, however, occur in virtually any 
CNS neoplasm including World Health Organization (WHO) grade I meningiomas, which are 
among the most common benign brain tumors. Rare subtypes of benign meningiomas such as 
angiomatous, microcystic and secretory meningioma may be associated with prominent 
perifocal edema. The presence of edema, therefore, is not a direct indicator of malignancy [1]. 
Therapeutic interventions on the tumor such as surgery, irradiation or chemotherapy may 
influence edema evolution [2-4]. Tumor-associated edema significantly contributes to the 
mass effect of CNS neoplasms and neurological deterioration. The pathophysiological 
mechanisms leading to the development of edema have been stepwise characterized in the last 
decades. The improved understanding of the molecular determinants underlying edema 
formation is a prerequisite for the development of novel therapeutic agents with anti-edema 
activity. 
 
 
Pathogenesis 
 
Peritumoral edema does not necessarily represent a single entity but may differ regarding their 
pathogenesis between meningiomas, gliomas and metastases. However, several basic 
mechanisms have been described as hallmarks of peritumoral edema. Similar to edema 
associated with abscess, tumor-related edema is considered to be vasogenic, that is, disturbed 
blood-brain barrier function resulting in increased vascular permeability. The altered vascular 
architecture in brain tumors results in loss of the barrier function and allows for a leakage of 
plasma fluid and proteins into the surrounding tissue [5]. Such a dysfunctional blood-brain 
barrier is found in high-grade gliomas but also many other malignant brain tumors.  
Tumor cells typically produce various cytokines which act on endothelial cells located within 
or around the tumor. Among others, the most important cytokine secreted by various brain 
tumors is vascular endothelial growth factor (VEGF) [6]. VEGF has initially been described 
as vascular permeability factor indicating that it is one of the most potent mediators of 
vascular permeability [7,8]. Under the influence of VEGF, the permeability of endothelium is 
increased resulting in a disturbance of the blood-brain barrier [9,10]. Tumor-derived VEGF 
may also enhance blood flow and induce vasodilatation [11]. It binds to different receptors 
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which are expressed by endothelial cells and also acts as a critical driver of angiogenesis in 
various neoplasms [12]. In many tumors such as gliomas, VEGF levels correlate with the 
grade of malignancy [13]. In meningiomas, the occurrence of brain edema is associated with 
increased VEGF levels which may contribute to edema evolution [14-16]. Similar 
mechanisms are present in metastatic brain tumors. They also release angiogenic factors 
acting on endothelial cells and promoting capillary formations characterized by various 
abnormalities. 
Besides VEGF, other factors which may be involved in the evolution of peritumoral edema 
comprise arachidonic acid metabolites and nitric oxide (NO). Increased leukotriene C4 
expression was noticed in brain tumors and may contribute to edema development by 
increasing the blood-brain barrier permeability [17]. Furthermore, the microenvironment 
surrounding brain tumors may also participate in the evolution of edema. Microglial cells 
infiltrating brain tumors are characterized by high expression levels of cyclooxygenase-2 
(COX-2) which generates prostaglandin E2 (PGE2). COX-2 is also expressed by glioma cells 
[18,19]. COX-2-derived PGE2, in turn, may promote the growth of experimental gliomas and 
contribute to edema development [20,21]. Similar mechanisms have been claimed for 
meningioma-associated edema [22]. VEGF-mediated NO expression through induction of 
endothelial nitric oxide synthase (eNOS) can promote vasodilation in brain tumors [23]. NO 
production in tumor endothelial cells may subsequently contribute to edema formation but its 
exact role has not been clarified [24,25]. 
Tumor vessels are characterized by fenestrations and pathological tight junctions [26,27]. 
Various molecules which contribute to the function of tight junctions such as claudins and 
occludin are down-regulated on tumor microvessels [28,29]. Intracellular molecules including 
Zonula Occludens (ZO)-1 and ZO-2 mediate an interaction of tight junction proteins with the 
endothelial cell cytoskeleton. Reduced expression levels of these proteins preclude 
appropriate function of tight junctions and results in fluid extravasation and evolution of 
edema. Furthermore, the functional activity of occludin and ZO-1 may be impaired by VEGF 
which subsequently translates into an opening of tight junctions [30]. 
Is has also been reported that increased glutamate levels secreted via the xCT transporter 
which is expressed by glioma cells contribute to the formation of peritumoral edema. 
Pharmacological or genetic inhibition of the xCT transporter resulted in a reduction of edema 
and prolonged survival of glioma-bearing rats [31]. Additional molecules which may be 
involved in the development of peritumoral edema include the family of aquaporins (AQP), a 
group of water channel proteins. AQPs are integral membrane proteins that are broadly 
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expressed in many cells. They are involved in the control of water flow into and out of cells 
[32]. AQP1 is overexpressed in tumor microvessel endothelia as well as glial and metastatic 
tumor cells [33]. In a similar study, increased AQP4 levels were observed in high-grade 
astrocytomas and brain metastases [34]. These authors noticed a correlation between blood-
brain barrier opening and increased AQP4 levels. AQP4 upregulation is also associated with 
brain edema formation in malignant gliomas [35]. Furthermore, AQP4 protein levels correlate 
with VEGF expression levels in gliomas [36]. AQP5 is highly expressed in meningiomas and 
correlates with the intensity of edema [37]. As a consequence, the upregulation of AQP 
family members may be implicated in the flow of edema fluid. However, their exact role in 
the evolution and persistence of peritumoral edema needs further investigation. 
 
 
Management of edema 
 
Steroids 
 
Vasogenic edema typically responds very well to corticosteroid treatment. Therefore, steroids 
are the most frequently used agents for the treatment of brain tumor-surrounding edema. The 
first reports, published in the 1950s, suggested a beneficial effect on the outcome of patients 
undergoing brain tumor surgery when cortisol or other drugs with glucocorticoid activity were 
administered perioperatively [38,39]. The availability of synthetic steroids such as prednisone 
or dexamethasone resulted in a rapid and widespread use of these agents in brain tumor 
patients. The mode of action of steroids, their clinical use as well as their important side 
effects have recently been reviewed in detail [40,41]. Therefore, the following section 
represents only a brief summary on some of the most important aspects of steroids as anti-
edematous agents. Dexamethasone is used by most neurooncologists because of its high 
glucocorticoid potency which is required for anti-edema therapy, hardly any 
mineralocorticoid side effects and a long biological half-life in the range of 48-54 h allowing 
for a daily single-dose administration. Hardly any data from placebo-controlled trials 
assessing the efficacy of steroids on the tumor-surrounding edema in brain tumors are 
available. However, there is not doubt on their distinct anti-edema activity resulting in a wide-
spread use all over the world. After administration, corticosteroids may result in rapid relief 
from neurological symptoms due to the reduction of the edematous mass. This effect, 
however, is typically transient and diminishes within weeks or months. Furthermore, the use 
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of steroids may be associated with significant toxicity precluding their unrestricted use. The 
most frequent acute side effects associated with the administration of steroids include 
hyperglycemia and arterial hypertension. Long-term intake frequently results in the 
development of osteoporosis, myopathy, psychiatric alterations, skin thinning and an 
increased risk for some opportunistic infections. Furthermore, steroids may reduce the 
sensitivity of tumor cells, other than lymphoma cells, to chemotherapeutic agents. 
Corticosteroids may also interfere with the metabolism of other therapeutics such as 
anticonvulsants, and vice versa. Therefore, steroid administration should be minimized 
whenever possible. However, despite these limitations, glucocorticoids remain the most 
important component in the treatment of peritumoral edema in brain cancer patients. 
 
 
Corticorelin acetate 
 
Human corticotropin-releasing factor (hCRF) is a naturally occurring neuropeptide which is 
produced in the hypothalamus [42]. It regulates the release of adrenocorticotropin hormone 
(ACTH) from the pituitary gland which subsequently induces hydrocortisone liberation from 
the adrenal gland. There are 2 hCRF receptors, CRF1 and CRF2, which are also expressed by 
numerous tumor cells [43]. Data from experimental glioma models suggest that hCRF may 
decrease tumor vascular permeability and vasogenic edema in vivo [44,45]. In these 
experiments, hCRF decreased the peritumoral edema also in adrenalectomized animals, 
pointing to a mode of action independent of the release of corticosteroids. It has been 
speculated that the anti-edematous effect of hCRF is due to a direct action on the 
microvasculature [46]. A phase I trial of hCRF in patients with peritumoral brain edema 
indicated that the drug is well tolerated when administered as a continuous infusion. Ten out 
of 17 patients experienced improvement of neurological symptoms whereas rather minor 
effects on the edema were observed by magnetic resonance imaging (MRI). Clinical 
improvement did not correlate with changes in cortisol levels [47]. Corticotropin acetate 
(CrA, Xerecept) is a synthetic analog of hCRF. When administered to glioma-bearing nude 
mice, it resulted in prolonged survival compared to dexamethasone- or temozolomide-treated 
animals [48]. The combination of CrA with bevacizumab in a rodent glioma model was 
associated with prolonged survival compared to either drug alone [49]. A prospective, 
randomized, double-blind study of 200 patients with primary and secondary brain tumors 
assessed the putative steroid-sparing effect of CrA. All patients had to be on a stable steroid 
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dose at enrolment. Patients within the CrA group received subcutaneous injections of 1 mg of 
the drug twice daily. CrA was well tolerated with injection site reactions as the only adverse 
event that was more prevalent in the CrA group. The primary end point, a reduction of the 
dexamethasone dose by 50% or more without worsening of neurological symptoms or 
performance status, showed a trend in favor of the CrA group without reaching statistical 
significance (p=0.12). However, the maximum percent reduction of the dexamethasone dose 
was more pronounced in the CrA group (62.7%) than in the control group (51.4%, p<0.001). 
Furthermore, patients receiving CrA were less frequently affected by myopathy and less likely 
to experience Cushingoid appearance [50]. Overall, these results are promising and CrA may 
represent a novel option allowing for a reduction of steroid administration in some patients. 
However, the steroid-sparing effects of CrA need further investigation. Future trials should 
define whether CrA administration may allow for a complete replacement of glucocorticoids 
in patients requiring only small steroid doses. 
 
 
Anti-angiogenic agents 
 
As outlined above, the abundant expression of VEGF in various brain tumors which are 
typically associated with significant perifocal edema has been recognized about 20 years ago 
[51]. In contrast, tumors which commonly lack large edemas such as pituitary adenomas are 
characterized by lower VEGF expression. Owing to its implication in the development of 
peritumoral edema, inhibition of VEGF signaling has been regarded as a promising 
therapeutic strategy for a long time. However, only within the last years, various agents 
targeting the VEGF pathway have become widely available.  
Bevacizumab is a humanized monoclonal antibody against VEGF-A which has been approved 
by the FDA for treatment of recurrent glioblastoma. In glioblastoma patients, bevacizumab 
administration frequently causes a distinct reduction in edema which is commonly associated 
with a reduction or even complete cessation of steroid administration [52,53]. MR imaging 
frequently demonstrates a reduction of peritumoral edema upon bevacizumab administration 
[54]. However, owing to its cost and the lack of approval in this indication, bevacizumab 
cannot be considered an alternative to steroids. Another agent which has been developed 
within the last years is the pan-VEGF receptor tyrosine kinase inhibitor cediranib. In a rodent 
glioma model, cedarinib prolonged survival of tumor-bearing mice due to its anti-edema 
action without inhibiting the growth of tumor cells proper [55]. Cediranib has also shown 
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efficacy in normalization of tumor vessels in recurrent glioblastoma patients and reduction of 
peritumoral edema [56]. A steroid-sparing effect of cediranib was also reported in a further 
series of patients with progressive glioblastoma [57]. However, the failure of the compound to 
prolong progression-free survival in a phase III study in patients with recurrent glioblastoma 
(NCT00777153), administered either alone or in combination with lomustine, has questioned 
the clinical activity of the compound [58]. Other novel agents targeting the VEGF pathway 
such as pazopanib, a multikinase angiogenesis inhibitor may be active against brain tumor-
surrounding edema but must currently be considered as an experimental approach in 
neurooncology [59]. 
 
 
Boswellic acids 
 
Boswellic acids, phytotherapeutic agents which are obtained by extraction from boswellia 
serrata, have been assessed for their anti-inflammatory properties and as putative anti-cancer 
drugs for many years. Boswellic acids are cytotoxic to glioma cells in vitro at low micromolar 
concentrations [60]. Furthermore, anti-edematous action has been described in a small series 
of brain tumor patients undergoing radio- or chemotherapy treated with the boswellia 
preparation H15 [61,62]. More recently, within a prospective trial 44 patients with primary or 
secondary malignant cerebral tumors were randomly assigned to receive radiotherapy plus 
either H15 or placebo. A reduction of cerebral edema of >75% assessed by T2-weighted MRI 
was observed in 60% of patients treated with H15 compared to 26% of patients receiving 
placebo (p=0.023). H15 was well tolerated except for minor gastrointestinal side effects in 
some patients. There was no significant difference in dexamethasone dose between the 2 
groups. Furthermore, treatment with H15 had no significant impact on quality of life or 
cognitive function [63]. The exact mode of action of boswellic acids on peritumoral edema 
has remained unclear but may partially rely on an interference with the VEGF pathway and 
suppression of PGE2 formation [64,65]. Overall, larger studies are required to assess the 
potential steroid-sparing effects of boswellic acids and their impact on therapy-related edema 
in more detail. Furthermore, a better understanding of the molecular mechanisms underlying 
the functional activity of boswellia extracts may help to exploit their full therapeutic potential. 
 
 
COX-2 inhibitors 
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COX-2 may contribute to the evolution of tumor-related edema as outlined above. Drugs 
which target COX-2 are widely available and have been partially assessed for their anti-
edematous efficacy. Celecoxib reduced VEGF expression levels in a preclinical tumor model 
[66]. The specific COX-2 inhibitor SC-236 was assessed in a rat brain tumor model and had a 
similar effect on survival than dexamethasone [67]. Rofecoxib inhibited the leakage of 
contrast medium in glioma-bearing rats to a similar amount as dexamethasone [20]. Whether 
these effects also occur in human patients and translate into clinical benefit has not been 
examined in detail. Case reports suggest a certain anti-edematous activity of COX-2 inhibition 
but confirmation in larger series is pending [68]. 
 
 
Other agents 
 
Osmotherapeutic agents such as mannitol, glycerol, or hypertonic saline are frequently used in 
patients suffering from extensive brain edema after stroke or trauma. The activity of these 
agents against brain tumor-related edema has not been examined systematically. These drugs 
lead to osmotic diuresis which may cause severe shifts in electrolyte levels. Furthermore, the 
“rebound phenomenon”, that is, edema recurrence upon treatment cessation, is a major 
limiting factor of their use. In a preclinical study, hypertonic saline given as a continuous 
intravenous infusion reduced the peritumoral edema in a rat brain tumor model [69]. 
However, because of the disrupted blood-brain barrier in many brain tumors, it must be 
considered that osmotherapeutics such as mannitol may leak into the brain parenchyma 
resulting in a further aggravation of the osmotic gradient [70]. Similarly, there are no data 
supporting a role for diuretics, e.g. furosemide, in the treatment of peritumoral edema. The 
use of osmotic agents should therefore be restricted to severely ill patients requiring 
immediate anti-edematous effects for a short period of time, e.g. during or after surgery. 
When steroids need to be avoided and this approach is considered clinically appropriate, e.g. 
in in patients with suspicion of lymphoma, osmotic agents may help to decrease edema-
derived mass effect preoperatively until a tissue specimen has been obtained for 
histopathological assessment.  
A small retrospective study analyzed the putative anti-edematous effects of angiotensin-II 
inhibitors in patients with newly diagnosed glioblastoma. It was reported that patients 
receiving angiotensin-II inhibitors, but not other antihypertensive drugs, required significantly 
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lower doses of steroids during radiotherapy [71]. This observation may be worth being 
pursued within a prospective trial. Other experimental treatments directed against peritumoral 
edema have only been assessed in preclinical studies: argatroban, a thrombin antagonist, 
reduced the peritumoral edema in a rodent glioma model [72]. Glyburide, a well-known 
antidiabetic drug, inhibits the sulfonylurea receptor 1 and reduced cerebral metastasis-related 
edema in rats [73]. Furthermore, caloric restriction attenuated the tumor-surrounding edema in 
glioma-bearing mice [74]. Whether any of these approaches will ever be assessed within 
clinical trials, needs to be awaited.  
 
 
Expert commentary 
 
Reducing the clinical burden derived from edema-mediated mass effect is an important task in 
patients with primary and secondary brain tumors. Glucocorticoids are the most frequently 
used agents against tumor-surrounding edema. They provide rapid albeit transient relief from 
clinical symptoms due to edema-mediated elevated intracranial pressure. Owing to their 
significant side effects, tapering should be considered whenever regarded clinically feasible. 
Even after several decades of research, convincing strategies that may allow for a significant 
reduction of steroids are lacking. An improved understanding of the underlying molecular 
mechanisms involved in the formation of peritumoral edema may help to develop novel 
therapeutic approaches. Inhibition of VEGF which may be the major player in the 
development of edemas in brain cancers results frequently in a considerable anti-edema effect. 
However, anti-VEGF therapies are expensive and far away from representing convincing 
alternatives to steroids. Boswellic acids, in contrast, have a more favourable price level and 
bear mostly only minor side effects. Based on the results of smaller patient series and a more 
recent larger trial, it may be concluded that they have a certain steroid-sparing effect. 
Therefore, it might be warranted to assess boswellic acids and their anti-edema efficacy in 
larger studies. 
 
 
Five-year view 
 
Alternatives which may help to reduce the long-term administration of steroids are urgently 
needed in order to avoid their manifold side effects. Based on data published by Recht et al. 
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[50], corticorelin acetate may currently be the most promising agent in this regard. However, 
several issues need further clarification such as the potential beneficial effects of the 
compound in patients who require rather small steroid doses. Whether corticorelin acetate in 
these patients may allow for a complete abstinence from steroids has not yet been examined. 
Furthermore, long-term toxicity as well as some safety issues, e.g. the combination with other 
compounds, is largely unknown. It remains to be seen whether the drug will be approved 
within the next years based on the available data. Further advances may arise from the 
ongoing research on H15 and similar boswellia serrata extracts. As with all other agents 
which have only been assessed within small series for their potential anti-edema activity, 
neurooncologists must strive for prospective, randomized-controlled trials in order to 
delineate their clinical use. Currently, no specific anti-edematous treatment based on the 
histology of the underlying tumor is available. A better understanding of the molecular 
mechanisms causing edema in different histological tumor entities may help to develop novel 
therapeutic strategies targeting edema. 
 
 
Key issues  
 
• Peritumoral edema can occur in virtually all CNS neoplasms and is most common in 
high-grade gliomas and metastases 
• Several factors contribute to the development of vasogenic edema including the 
secretion of VEGF by tumor cells 
• The mass effect derived from tumor-associated edema increases intracranial pressure 
and results in neurological symptoms, significantly contributing to morbidity 
• Steroids are the mainstay of anti-edematous therapy. Their administration frequently 
leads to clinical improvement and symptom relief 
• The mid- and long-term use of steroids is limited due to their numerous side effects 
such as metabolic changes, osteoporosis, myopathy, increased risk for opportunistic 
infections, psychiatric alterations and many more 
• Corticorelin acetate, a synthetic analog of corticotropin releasing factor, may help to 
reduce steroids doses and steroid-related side effects 
• Anti-angiogenic agents such as the VEGF inhibitor bevacizumab have pronounced 
anti-edema effects in many brain tumor patients 
12 
 
• Several agents with putative anti-edematous activity have only been assessed in 
preclinical models or small patients series including COX-2 and angiotensin-II 
inhibitors and further clinical testing is required 
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